Lovastatin: a new “ancient” molecule for hypercholesterolaemia/dyslipidaemia treatment

Lovastatin: a new “ancient” molecule for hypercholesterolaemia/dyslipidaemia treatment

Authors

  • Gianlorenzo Imperiale Dirigente, S.C. Medicina Interna, ASL TO1, Ospedale “Martini”.Responsabile Ambulatorio di Medicina Interna e Ambulatorio delle Dislipidemie e dell’Aterosclerosi
  • Claudio Marengo Direttore, S.C. Medicina Interna Ospedale Santa Croce, Moncalieri (TO) e Dipartimento Area Medica, ASL TO5

DOI:

https://doi.org/10.7175/cmi.v2i2.577

Keywords:

HMGCoA-reductase inhibitors, Lovastatin, Hypercholesterolaemia, Dyslipidaemia, Cardiovascular disease, Prevention, Economic cost

Abstract

Lovastatin is the first HMGCoA-reductase inhibitor used for the control of hypercholesterolaemia (USA, 1987). In Italy, it’s been authorized for the therapy of hypercholesterolaemia/dyslipidaemia since end 2005. Several studies, conducted both in primary and in secondary cardiovascular prevention, underline the favourable profile in reducing the risk for ischaemic events and their complications. This molecule has the capability to reduce plasmatic atherogenic lipids levels enough to induce clinical benefits. The safety and tolerability of lovastatin are proved even for high dosages, as well as for long term use. Pharmacoeconomic evaluations have shown the value of its choice, in particular for patients who need lipid-lowering treatment but don’t satisfy eligibility criteria for reimbursement by the Italian National Health Service, as outlined by AIFA in 2005.

Downloads

Published

2008-06-15

Issue

Vol. 2 No. 2 (2008)

Section

Clinical management

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)